First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone ...

Aliya Omer, VP, US franchise head, breast cancer, AstraZeneca, discusses Lynparza’s role in reducing the risk of invasive disease recurrence or death in HR-positive breast cancer patients.

There are three types of PARP inhibitors approved to treat ovarian cancer — olaparib (Lynparza), rucaparib (Rubraca), and niraparib (Zejula). The drugs are largely similar in how they work with slight ...

A study led by the Joe C. Wen School of Population & Public Health at the University of California, Irvine has revealed possible links between exposure to per- and polyfluoroalkyl substances in ...

Department of Gastrointestinal Surgery, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Henan Provincial Research Center for Precision Control Engineering of Digestive ...

Olaparib (Lynparza, AstraZeneca) is indicated as 'monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2 negative locally advanced or metastatic breast cancer.

Ltd. announces the release of a market assessment report on the “Global PARP Inhibitors Market Size, Share & Trends Analysis Report By Product (Niraparib (Zejula), Olaparib (Lynparza), Rucaparib ...

AZ and Merck said that the approval makes Lynparza (olaparib) the only PARP inhibitor to have shown an improvement in overall survival when used in this setting, ahead of rivals like Clovis ...

Combining the PARP inhibitor olaparib (Lynparza) and the monoclonal antibody bevacizumab (Avastin) has shown to extend the length of time before ovarian cancer progressed or recurred. Women with ...

The cost-effectiveness body in final draft guidance said the Cancer Drugs Fund should reimburse Lynparza (olaparib) in adults with advanced high-grade epithelial ovarian, fallopian tube ...